Skip to main content
Log in

La malattia di von Hippel-Lindau

  • Published:
L’Endocrinologo Aims and scope

Riassunto

La malattia di von Hippel-Lindau è una sindrome neoplastica multisistemica a trasmissione autosomica dominante, penetranza completa ed espressività variabile causata da un difetto del gene VHL. La mancanza o l’insufficienza del prodotto proteico del gene VHL, attraverso la mancata distruzione di HIF e la conseguente iperespressione di geni coinvolti nell’angiogenesi, conduce allo sviluppo di svariati tumori, benigni o maligni, e cisti in molti sistemi ed apparati. Gli individui affetti ereditano la predisposizione allo sviluppo di lesioni al SNC quali emangioblastomi cerebellari, spin ali, del tronco cerebrale, delle radici nervose e sopratentoriali, ed inoltre emangioblastomi retinici e tumori del sacco endolinfatico. Le lesioni viscerali includono carcinomi renali a cellule chiare, feocromocitomi, cisti renali e pancreatiche, tumori endocrini del pancreas, cistoadenomi papillari dell’epididimo e del legamento largo, emangiomi del fegato e del polmone. Quindi nella malattia di von Hippel- Lindau vi sono almeno due neoplasie di ghiandole endocrine, la midollare del surrene e l’insula pancreatica. Inoltre, anche paragangliomi della testa e del collo sono stati descritti in pazienti con malattia di VHL. Le varie lesioni tipich e del von Hippel- Lindau mostrano una costante progressione nel tempo per cui, in questi pazienti, risulta fondamentale un follow-up clinico volto alla prevenzione delle complicanze. L’unica terapia attualmente disponibile è quella chirurgica ma sono in corso di valutazione trattamenti farmacologici con inibitori delle kinasi.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Bibliografia

  1. Woodward ER, Maher ER. Von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr Relat Cancer 13: 415, 2006.

    Article  CAS  PubMed  Google Scholar 

  2. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317, 1993.

    Article  CAS  PubMed  Google Scholar 

  3. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Li H, Wei MH, Schmidt L, Tory K, Kuzman I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5: 66, 1995.

    Article  CAS  PubMed  Google Scholar 

  4. Murgia A, Martella M, Vinanzi C, Polli R, Perilongo G, Opocher G. Somatic mosaicism in von Hippel-Lindau Disease. Hum Mutat 15: 114, 2000.

    Article  CAS  PubMed  Google Scholar 

  5. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F., Maher, E.R. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28: 143, 2006.

    Article  Google Scholar 

  6. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER. Contrasting effects on HIF- 1 -alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Molec Genet 10: 1029, 2001.

    Article  CAS  PubMed  Google Scholar 

  7. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr. HIF-alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O(2) sensing. Science 292: 464, 2001.

    Article  CAS  PubMed  Google Scholar 

  8. Allen RC, Webster AR, Sui R, Brown J, Taylor CM, Stone EM. Molecular characterization and ophthalmic investigation of a large family with type 2A von Hippel-Lindau disease. Arch Ophthalm 119: 1659, 2001.

    Article  CAS  Google Scholar 

  9. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. von Hippel-Lindau disease. Lancet 361: 2059, 2003.

    Article  CAS  PubMed  Google Scholar 

  10. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 98: 82, 2003.

    Article  PubMed  Google Scholar 

  11. Gallou C, Chauveau D, Richard S, Joly D, Giraud S, Olschwang S, Martin N, Saquet C, Chretien Y, Mejean A, Correas JM, Benoit G, Colombeau P, Grunfeld JP, Junien C, Beroud C. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum Mutat 24: 215, 2004.

    Article  CAS  PubMed  Google Scholar 

  12. Bender BU, Gutsche M, Glasker S, Muller B, Kirste G, Eng C, Neumann HPH. Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 85: 4568, 2000.

    CAS  PubMed  Google Scholar 

  13. Crossey PA, Eng C, Ginalska-Malinowska M, Lennard TW J, Wheeler DC, Ponder BA J, Maher ER. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J Med Genet 32: 885, 1995.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, Chauveau D, Balian A, Beigelman C, O’Toole D, Bernades P, Ruszniewski P, Richard S. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d’Etude de la Maladie de von Hippel-Lindau. Gastroenterology 119: 1087, 2000.

    Article  CAS  PubMed  Google Scholar 

  15. Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, Linehan WM, Glenn GM, Choyke PL. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology 225: 751, 2002.

    Article  PubMed  Google Scholar 

  16. Kim HJ, Butman JA, Brewer C, Zalewski C, Vortmeyer AO, Glenn G, Oldfield EH, Lonser RR. Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg 102: 503, 2005.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giuseppe Opocher.

Additional information

Rete VHL dell’Ospedale Università di Padova; Giuseppe Opocher: coordinatore, patologia endocrina; Alessandra Murgia, Maddalena Martella: genetica molecolare; Stefano Piermarocchi: patologia oculare; Renato Scienza, Giacomo Pavesi, Silvia Berlucchi: patologia neurochirurgica; Walter Artibani, Vincenzo Ficarra: patologia nefro-urologica; Eva Orzan: patologia otochirurgica; Maria Rosa Pelizzo, Antonio Toniato: patologia chirurgica; Associazione Italiana Famiglie VHL - ONLUS (www.vhl.it).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opocher, G., Feletti, A., Pavesi, G. et al. La malattia di von Hippel-Lindau. L’Endocrinologo 8, 102–108 (2007). https://doi.org/10.1007/BF03344570

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344570

Navigation